Meeting
2018 ASCO Annual Meeting
Phase I trial of lurbinectedin (PM1183) in Japanese patients with advanced tumors: Results of the dose escalation part.
Authors
Shunji Takahashi
Cancer Institute Hospital of JFCR, Tokyo, Japan
Shunji Takahashi , Toshio Shimizu , Toshihiko Doi , Jose Antonio Lopez-Vilariño , Rafael Nuñez , Carmen Maria Kahatt , Carlos Fernandez , Katrin Zaragoza , Hiromi Sasamoto , Arturo Soto-Matos
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Other Novel Agents
Clinical Trial Registration Number
NCT02210364
Citation
J Clin Oncol 36, 2018 (suppl; abstr 2551)
DOI
10.1200/JCO.2018.36.15_suppl.2551
Abstract #
2551
Poster Bd #
377
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
A phase I trial of mifepristone (M), carboplatin (C), and gemcitabine (G) in advanced breast and ovarian cancer.
First Author: Erica Michelle Stringer
Poster
2014 ASCO Annual Meeting
A phase I trial of palbociclib and paclitaxel in metastatic breast cancer.
First Author: Amy Sanders Clark
Poster
2023 ASCO Breakthrough
MEKiAUTO: A multicenter phase 1 study of combination therapy with the MEK inhibitor, cobimetinib, immune checkpoint blockade, atezolizumab, and the autophagy inhibitor hydroxychloroquine (HCQ) in KRAS-mutated advanced malignancies.
First Author: Gulam Abbas Manji
Poster
2023 ASCO Annual Meeting
Phase I study of MP0317, a FAP-dependent DARPin, for tumor-localized CD40 activation in patients with advanced solid tumors.
First Author: Carlos A. Gomez-Roca